GoAI
Get started
Nippon Chemiphar Co., Ltd. logo

Nippon Chemiphar Co., Ltd.

4539.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Latest quote

¥1,587

+¥19.00 · +1.21%

Aug 24, 10:14 AM JST

4539.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Nippon Chemiphar Co., Ltd., alongside its subsidiaries, is a global pharmaceutical entity engaged in the research, production, marketing, and sale of ethical drugs and diagnostic agents. Its diagnostic product lineup features the IgE NC kit, which measures overall IgE levels and identifies 57 specific allergens, as well as the DP3000 device for accurate allergen-specific IgE testing. The company's development pipeline includes NC-2400, a PPAR-delta agonist; NC-2500, a novel xanthine oxidoreductase inhibitor targeting hyperuricemia and gout; and NC-2600, a P2X4 receptor antagonist for neuropathic pain. Additionally, it is advancing NC-2700, a new urate transporter 1 inhibitor designed to enhance urinary urate excretion, and NC-2800, a delta opioid receptor agonist for treating depression and anxiety. Its commercialized pharmaceuticals comprise Uralyt-U (an alkalization therapeutic), Soleton (an analgesic and anti-inflammatory medication), and Calvan (a drug for hypertension). Beyond pharmaceuticals, Nippon Chemiphar offers a variety of quasi-drugs, nutritional supplements, health foods, cosmetics, and different types of creams. Its generic medications reach hospitals and pharmacies via wholesale distributors. Founded in Tokyo, Japan, in 1950, the company was initially known as Hitachi Chemical Co., Ltd., changing its name to Nippon Chemiphar Co., Ltd. in 1970.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Kazushiro Yamaguchi
Listed since
Jan 1, 2001
Employees
878

Market position

Volume
3.1K
1.87× average
Average volume
1.66K
Average daily volume
Market cap
5.75B JPY
Beta
0.19
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
17.67B JPY
P/E (TTM)
-46.21×
P/B (TTM)
0.3×
P/S (TTM)
0.17×
EV / EBITDA
8.82×
Earnings yield
3.08%
Free cash flow yield
-3.59%
Dividend yield
3.15%

Profitability & efficiency

Gross margin
24.38%
Operating margin
-0.94%
Net margin
-0.38%
Return on equity
1.01%
Return on assets
0.40%
Return on invested capital
0.40%

Financial health

Debt / equity
0.96×
Current ratio
2.36×
Altman Z-score
1.52
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends31%19%7%-5%Gross margin, FY2021: 27.91%Gross margin, FY2022: 25.94%Gross margin, FY2023: 25.17%Gross margin, FY2024: 26.85%Gross margin, FY2025: 25.38%Operating margin, FY2021: 2.54%Operating margin, FY2022: -0.76%Operating margin, FY2023: -1.61%Operating margin, FY2024: 1.86%Operating margin, FY2025: 0.54%Net margin, FY2021: 2.15%Net margin, FY2022: 1.07%Net margin, FY2023: -0.59%Net margin, FY2024: 0.90%Net margin, FY2025: 0.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.91%. Gross margin FY2022 25.94%. Gross margin FY2023 25.17%. Gross margin FY2024 26.85%. Gross margin FY2025 25.38%. Operating margin FY2021 2.54%. Operating margin FY2022 -0.76%. Operating margin FY2023 -1.61%. Operating margin FY2024 1.86%. Operating margin FY2025 0.54%. Net margin FY2021 2.15%. Net margin FY2022 1.07%. Net margin FY2023 -0.59%. Net margin FY2024 0.90%. Net margin FY2025 0.60%.

Income trends

Revenue

33.09B JPY+1.60%

Operating income

180M JPY-70.35%

Net income

198M JPY-32.65%
Income trends across reported periods36.45B JPY23.01B JPY9.58B JPY−3.85B JPYRevenue, FY2021: 32.51B JPYRevenue, FY2022: 31.56B JPYRevenue, FY2023: 30.75B JPYRevenue, FY2024: 32.57B JPYRevenue, FY2025: 33.09B JPYOperating income, FY2021: 825M JPYOperating income, FY2022: −241M JPYOperating income, FY2023: −494M JPYOperating income, FY2024: 607M JPYOperating income, FY2025: 180M JPYNet income, FY2021: 700M JPYNet income, FY2022: 339M JPYNet income, FY2023: −180M JPYNet income, FY2024: 294M JPYNet income, FY2025: 198M JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 32.51B JPY. Revenue FY2022 31.56B JPY. Revenue FY2023 30.75B JPY. Revenue FY2024 32.57B JPY. Revenue FY2025 33.09B JPY. Operating income FY2021 825M JPY. Operating income FY2022 −241M JPY. Operating income FY2023 −494M JPY. Operating income FY2024 607M JPY. Operating income FY2025 180M JPY. Net income FY2021 700M JPY. Net income FY2022 339M JPY. Net income FY2023 −180M JPY. Net income FY2024 294M JPY. Net income FY2025 198M JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue33.09B JPY32.57B JPY30.75B JPY31.56B JPY32.51B JPY
Cost of goods sold24.69B JPY23.82B JPY23.01B JPY23.37B JPY23.43B JPY
Gross profit8.4B JPY8.75B JPY7.74B JPY8.19B JPY9.07B JPY
Research and development—2.29B JPY2.33B JPY2.42B JPY2.39B JPY
Selling, general, and administrative8.22B JPY8.14B JPY5.91B JPY6.01B JPY5.86B JPY
Operating expenses8.22B JPY8.14B JPY8.23B JPY8.43B JPY8.25B JPY
Interest income10M JPY5M JPY3M JPY2M JPY—
Interest expense225M JPY198M JPY150M JPY122M JPY118M JPY
Depreciation and amortization1.56B JPY1.38B JPY1.46B JPY1.5B JPY1.59B JPY
Operating income180M JPY607M JPY−494M JPY−241M JPY825M JPY
Net income198M JPY294M JPY−180M JPY339M JPY700M JPY

Company facts updated Aug 24, 2026.

Corporate actions

Corporate action history

Stock split

Effective Sep 28, 2016

1:10

4539.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥7,008

-0.04%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,799

+0.61%

HOYA Corporation logo

7741.T

HOYA Corporation

¥24,990

+0.38%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,205

+0.08%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,862

+1.01%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,392.5

+0.23%

Continue in GoAI

Research 4539.T

research.disclaimer